N@N

Jason Gerberry Reiterated (AXSM) at Sell and Held Target at $52 on, Feb 14th, 2023

Jason Gerberry of B of A Securities, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Sell and Held Target at $52 on, Feb 14th, 2023.

Jason has made no other calls on AXSM in the last 4 months.

There are 7 other peers that have a rating on AXSM. Out of the 7 peers that are also analyzing AXSM, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• David Amsellem of "Piper Sandler" Initiated at Hold and Held Target at $75 on, Thursday, January 5th, 2023
• Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $86 on, Tuesday, November 29th, 2022

These are the ratings of the 5 analyists that currently disagree with Jason

---

• Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $86 on, Monday, January 30th, 2023
• Robert Hazlett of "BTIG" Maintained at Strong Buy with Increased Target to $98 on, Friday, December 23rd, 2022
• Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $85 on, Tuesday, November 29th, 2022
• Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $80 on, Friday, November 11th, 2022
• Esther Hong of "Loop Capital" Initiated at Strong Buy and Held Target at $95 on, Tuesday, November 1st, 2022

Contributing Sources

---